S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:PHVS

Pharvaris (PHVS) Stock Price, News & Analysis

$23.11
-0.39 (-1.66%)
(As of 03/28/2024 ET)
Today's Range
$21.16
$23.61
50-Day Range
$21.26
$32.07
52-Week Range
$7.00
$33.00
Volume
8,740 shs
Average Volume
77,259 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.50

Pharvaris MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
40.6% Upside
$32.50 Price Target
Short Interest
Healthy
0.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.44mentions of Pharvaris in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.30) to ($2.15) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.73 out of 5 stars

Medical Sector

494th out of 939 stocks

Pharmaceutical Preparations Industry

237th out of 444 stocks

PHVS stock logo

About Pharvaris Stock (NASDAQ:PHVS)

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

PHVS Stock Price History

PHVS Stock News Headlines

Pharvaris' (PHVS) "Outperform" Rating Reaffirmed at Wedbush
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Pharvaris Announces Extraordinary Meeting of Shareholders
Pharvaris Announces Extraordinary Meeting of Shareholders
Wedbush Reaffirms Their Buy Rating on Pharvaris (PHVS)
Pharvaris to Present at the WSAAI Annual Meeting 2024
Pharvaris: Digging Deep For Sufficient Market Size
See More Headlines
Receive PHVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/29/2024
Next Earnings (Estimated)
4/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PHVS
Fax
N/A
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.50
High Stock Price Target
$49.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+40.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-80,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.94 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
-3.12
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Berndt Axel Edvard Modig CPA (Age 65)
    M.B.A., Co-Founder, CEO & Executive Director
    Comp: $543.05k
  • Ms. Anna Nijdam M.Sc. (Age 43)
    R.A., Head of Strategic Finance & Principal Accounting Officer
  • Ms. Joan Schmidt J.D. (Age 60)
    Chief Legal Officer
  • Dr. Peng Lu M.D. (Age 46)
    Ph.D., Chief Medical Officer
  • Dr. Anne A. Lesage Ph.D. (Age 63)
    Chief Early Development Officer
  • Dr. Morgan Conn Ph.D. (Age 55)
    Chief Business Officer
  • Mr. Wim Souverijns Ph.D. (Age 53)
    Chief Community Engagement & Commercial Officer
  • Dr. Stefan Abele Ph.D. (Age 54)
    Chief Technology Operations Officer
  • Maryann Cimino
    Director of Corporate Relations
  • Ms. Annick Deschoolmeester (Age 51)
    Chief Human Resources Officer

PHVS Stock Analysis - Frequently Asked Questions

Should I buy or sell Pharvaris stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pharvaris in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PHVS shares.
View PHVS analyst ratings
or view top-rated stocks.

What is Pharvaris' stock price target for 2024?

4 brokers have issued 1-year price targets for Pharvaris' shares. Their PHVS share price targets range from $11.00 to $49.00. On average, they predict the company's stock price to reach $32.50 in the next year. This suggests a possible upside of 40.6% from the stock's current price.
View analysts price targets for PHVS
or view top-rated stocks among Wall Street analysts.

How have PHVS shares performed in 2024?

Pharvaris' stock was trading at $28.05 at the beginning of the year. Since then, PHVS stock has decreased by 17.6% and is now trading at $23.11.
View the best growth stocks for 2024 here
.

Are investors shorting Pharvaris?

Pharvaris saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 14,900 shares, a decrease of 85.3% from the February 29th total of 101,600 shares. Based on an average daily trading volume, of 110,500 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.2% of the shares of the stock are short sold.
View Pharvaris' Short Interest
.

When is Pharvaris' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our PHVS earnings forecast
.

How were Pharvaris' earnings last quarter?

Pharvaris (NASDAQ:PHVS) posted its earnings results on Wednesday, November, 10th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.10.

When did Pharvaris IPO?

Pharvaris (PHVS) raised $126 million in an IPO on Friday, February 5th 2021. The company issued 7,000,000 shares at $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink served as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers.

Who are Pharvaris' major shareholders?

Pharvaris' stock is owned by a number of retail and institutional investors. Top institutional investors include venBio Partners LLC (15.45%), Bain Capital Life Sciences Investors LLC (0.00%), Viking Global Investors LP (11.49%), Novo Holdings A S (4.83%), Price T Rowe Associates Inc. MD (2.65%) and Price T Rowe Associates Inc. MD (0.00%).

How do I buy shares of Pharvaris?

Shares of PHVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PHVS) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners